The first public disclosure under the EFPIA transparency directive was made on 30th June, 2016, while the first data set was received in June of 2015. During this time, the press had questioned the rates of consent received from physicians in reporting spend details, but they failed to acknowledge the timely delivery of most reports and a voluntary step to disclose the spend by EFPIA members.
Join us as qordata’s Practice Leader Life Science, Ned Mumtaz, presents a detailed review of the EFPIA transparency directive, physician spend numbers and delves into information pertaining to the countries that require/do not require consent along with future predictions. In this educational webinar, Ned will provide insights into practices and strategies of pharmaceutical companies in EU countries for managing transparency and disclosure reporting. He will further dive into disclosed physician spend numbers from various member countries. The webinar will conclude on a note on how companies may start using consent management initiatives as a driver for improving the rate of consent.
Take Away From This Webinar:
Attendees will receive a detailed analysis of EFPIA physician spend numbers, consent rates and the initiatives being taken by companies to increase the rate of consent.
Practice Leader Life Science at qordata
Ned Mumtaz has over 20 years of experience in the pharmaceutical industry. As the Practice Director for Pharmaceutical Services at qordata, he is leading the transparency directive
Head of Marketing at qordata
Zafar Ahmed, Head of Marketing at qordata, will be moderating the webinar.
- Review consent rate in various EFPIA member countries
- Deliberate upon physician spend details
- Deliver insights into disclosure reporting practices of pharma companies in EU
- Assess the initiatives companies can take to increase consent rates
October 27th, 2016 at 11 am CST
(Jeudi) 11 h 00 min - 12 h 00 min